Strong science and early support are not enough on their own. Europe needs more capital depth, cross-border investor backing and a lighter policy framework to keep companies scaling at home, according to two venture capitalists.

Original title: “Germany can produce biotech winners. Europe must back them better.”

Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.

Original title: “Niowave, fresh from Novartis deal, starts building $75M radioisotope plant”

Eli Lilly, with a busier-than-ever business development team, has made a major vaccine play‚ months after hiring veteran vaccine regulator Peter Marks following his FDA departure.

Original title: “Lilly lands vaccine trifecta with 3 new biotech buys valued at up to $3.8B”

The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and steering dollars away from “half-baked ideas.”

Original title: “SR One’s Simeon George on how China is rewriting biotech’s venture playbook”

Uncover four key misconceptions that could be holding your intensification strategies back — and how to set your initiatives up for success.

Original title: “Process intensification: Separating fact from fiction”

Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.

Original title: “All eyes on Revolution, bispecific antibodies and more at ASCO26”

The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.

Original title: “4 troubled targets that have thwarted biopharma”